Acer Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for serious and life-threatening diseases with unmet medical needs. The company was founded in 2013 and is based in Newton, Massachusetts.
Acer Therapeutics Inc. is focused on developing therapies for rare and ultra-rare diseases. The company's lead product candidate, Edsivo (celiprolol), is being developed for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a rare genetic disorder that affects the connective tissue in blood vessels and organs. Edsivo has received Orphan Drug Designation from the FDA and is currently in a Phase 3 clinical trial.
Acer Therapeutics Inc. is also developing ACER-001, a taste-masked, immediate-release formulation of sodium phenylbutyrate, for the treatment of urea cycle disorders (UCDs), a group of rare genetic disorders that affect the body's ability to process nitrogen. ACER-001 has received Orphan Drug Designation from the FDA and is currently in a Phase 3 clinical trial.
The company's pipeline also includes ACER-801, a potential treatment for Maple Syrup Urine Disease (MSUD), a rare genetic disorder that affects the body's ability to break down certain amino acids. ACER-801 is currently in preclinical development.
Acer Therapeutics Inc. is committed to bringing innovative therapies to patients with rare diseases, with a focus on improving patient outcomes and quality of life. The company works closely with patient advocacy groups and other stakeholders to ensure that the needs of patients with rare diseases are addressed and that its therapies are developed in a patient-centric manner.
The COVID-19 pandemic has presented challenges for the healthcare industry, including disruptions to clinical trials and changes in healthcare delivery. However, Acer Therapeutics Inc. has continued to advance its clinical programs, with plans to initiate additional clinical trials in the near future.
Acer Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare diseases. The company's pipeline includes potential treatments for vascular Ehlers-Danlos syndrome, urea cycle disorders, and Maple Syrup Urine Disease. With its focus on innovation and patient-centered approach, Acer Therapeutics Inc. is well-positioned to continue driving innovation and growth in the healthcare industry.